Mapi Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Mapi Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C11271)・商品コード:DATA904C11271
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:30
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Mapi Pharma Ltd (Mapi Pharma) is a clinical stage pharmaceutical company that offers development of active pharmaceutical ingredients and formulations, and life cycle management products. The company’s lead products include Glatiramer Acetate Depot, an injection for the treatment of multiple sclerosis and Risperidone LAI, a long acting injection for the treatment of schizophrenia and bipolar disorder. It also develops Pregabalin ER, extended release oral capsules for the treatment of neuropathic pain and epilepsy. Mapi Pharma also provides development of finished dosage formulations and complex APIs for the development, and manufacture and sale of generic pharmaceuticals. The company operates research and development facilities in Israel and China. Mapi Pharma is headquartered in Ness Ziona, Israel.

Mapi Pharma Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Mapi Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Mapi Pharma Raises USD10 Million in Venture Financing 10
Mapi Pharma Raises USD10 Million in Series A Financing 11
Partnerships 12
Mapi-Pharma Enters Into Partnership Agreement with Jiangsu Nhwa Pharmaceutical 12
Mapi Pharma Enters into Agreement with Taro Pharma 13
Mapi Pharma Enters into Co-Development Agreement with Jiangsu Nhwa Pharma 14
Mapi Pharma Amends Co-Development Agreement With Merck 15
Licensing Agreements 16
Stem Cell Medicine Enters into Licensing Agreement with Mapi Pharma 16
Equity Offering 17
Mapi Pharma Raises USD10 Million in Private Placement of Shares 17
Jiangsu Nhwa Pharma to Invest Funds in Mapi Pharma 18
Mapi Pharma Withdraws IPO of Shares up to USD53 Million 19
Mapi Pharma to Raise USD10 Million in Private Placement of Shares 21
Asset Transactions 22
Mylan to Acquire Marketing Rights to GA Depot from Mapi Pharma 22
Mapi Pharma Ltd – Key Competitors 23
Mapi Pharma Ltd – Key Employees 24
Mapi Pharma Ltd – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Product News 26
02/06/2018: Mapi Pharma to Host Key Opinion Leader Meeting on Long Acting Glatiramer Acetate (GA Depot) for Multiple Sclerosis 26
Clinical Trials 27
Oct 09, 2018: Mapi Pharma Presents Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at ECTRIMS 2018 in Berlin 27
Jan 30, 2018: First Patient Treated in Mapi Pharma’s Phase II Clinical Trial of GA Depot for Primary Progressive Multiple Sclerosis 28
Oct 31, 2017: Mapi Pharma Announces Presentation of Phase II Results of Glatiramer Acetate Depot at ECTRIMS-ACTRIMS 2017 Congress in Paris 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Mapi Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Mapi Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Mapi Pharma Raises USD10 Million in Venture Financing 10
Mapi Pharma Raises USD10 Million in Series A Financing 11
Mapi-Pharma Enters Into Partnership Agreement with Jiangsu Nhwa Pharmaceutical 12
Mapi Pharma Enters into Agreement with Taro Pharma 13
Mapi Pharma Enters into Co-Development Agreement with Jiangsu Nhwa Pharma 14
Mapi Pharma Amends Co-Development Agreement With Merck 15
Stem Cell Medicine Enters into Licensing Agreement with Mapi Pharma 16
Mapi Pharma Raises USD10 Million in Private Placement of Shares 17
Jiangsu Nhwa Pharma to Invest Funds in Mapi Pharma 18
Mapi Pharma Withdraws IPO of Shares up to USD53 Million 19
Mapi Pharma to Raise USD10 Million in Private Placement of Shares 21
Mylan to Acquire Marketing Rights to GA Depot from Mapi Pharma 22
Mapi Pharma Ltd, Key Competitors 23
Mapi Pharma Ltd, Key Employees 24

List of Figures
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Mapi Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Mapi Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C11271)販売に関する免責事項を必ずご確認ください。
★調査レポート[Mapi Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆